Awards Registry

Minimally Invasive VAD for Treatment of Acute Right Heart Failure
Profile last edited on: 3/2/2022

Program
SBIR
Agency
NIH | NHLBI
Total Award Amount
$999,794
Award Phase
2
Principal Investigator
Scott C Corbett
Activity Indicator

Company Information

ABIOMED Inc (AKA:Applied Biomedical Corporation)

22 Cherry Hill Drive
Danvers, MA 01923
   (978) 646-1400
   abmd@abiomed.com
   www.abiomed.com
Multiple Locations:   
Congressional District:   06
County:   Essex

Phase I

Phase I year
2009
Phase I Amount
$499,832
This application addresses broad Challenge Area (04) Clinical Research and Specific Challenge Topic 04-HL-110 Treatment of pulmonary hypertension and right heart failure. The overall objective of this proposed program is the U.S. clinical introduction of the Impella RP system, a percutaneously introduced ventricular assist device (VAD) for treatment of acute right heart failure. The device will be a less traumatic alternative to surgically placed extracorporeal right ventricular assist devices (RVADs), the current standard of care for these patients. The Impella RP system is designed to reduce the workload of the right ventricle and promote cardiac recovery, providing flows of up to 4 lpm and up to 2 weeks of support. The program will comprise pre-clinical design verification and validation testing, regulatory filings to the FDA, and an Investigational Device Exemption (IDE) clinical trial to evaluate safety and effective hemodynamic support. Based upon the success of our proposed program, the next steps would be an application for FDA approval to market the device in the U.S. and preparation for clinical introduction.

Public Health Relevance:
Acute right heart failure is a significant clinical problem which often occurs in patients affected by pulmonary embolism, pulmonary hypertension, or heart attack, as well as in patients who have been treated with cardiopulmonary bypass, heart transplantation, or left heart mechanical circulatory support. Right ventricular failure that does not respond to medication is treated with mechanical circulatory support in the form of a right ventricular assist device (RVAD). Current surgically placed RVADs offer potential for rapid recovery, but are highly invasive and are associated with a host of complications including blood clots and bleeding. Therefore, a strong unmet clinical need exists for a minimally invasive and percutaneously placed RVAD that requires only a minimal level of anticoagulation. We estimate that up to 25,000 patients each year could benefit from such a short term RVAD.

Public Health Relevance Statement:
PROJECT NARRATIVE Acute right heart failure is a significant clinical problem which often occurs in patients affected by pulmonary embolism, pulmonary hypertension, or heart attack, as well as in patients who have been treated with cardiopulmonary bypass, heart transplantation, or left heart mechanical circulatory support. Right ventricular failure that does not respond to medication is treated with mechanical circulatory support in the form of a right ventricular assist device (RVAD). Current surgically placed RVADs offer potential for rapid recovery, but are highly invasive and are associated with a host of complications including blood clots and bleeding. Therefore, a strong unmet clinical need exists for a minimally invasive and percutaneously placed RVAD that requires only a minimal level of anticoagulation. We estimate that up to 25,000 patients each year could benefit from such a short term RVAD.

NIH Spending Category:
Assistive Technology; Bioengineering; Cardiovascular; Clinical Research; Heart Disease; Heart Disease - Coronary Heart Disease; Lung; Rehabilitation

Project Terms:
Acute; Acute myocardial infarct; Acute myocardial infarction; Address; Affect; Anticoagulation; Area; Artificial Heart; base; Bleeding; Blood; Blood Clot; Blood Clotting; Blood coagulation; blood loss; blood pump; Cardiac; cardiac failure; cardiac graft; cardiac infarct; Cardiac infarction; cardiac prosthesis; Cardiopulmonary Bypass; Cathetergram; Catheterization; Catheters; Characteristics; Clinical; clinical investigation; Clinical Research; Clinical Study; Clinical Trials; Clinical Trials, Unspecified; coronary attack; coronary infarct; coronary infarction; cost; design; designing; Development; Device Designs; Devices; drug/agent; Drugs; Effectiveness; experiment; experimental research; experimental study; failure; Failure (biologic function); Family suidae; Femoral vein; FLR; Funding; Grafting, Heart; heart attack; heart bypass; Heart failure; heart infarct; heart infarction; heart prosthesis; heart transplant; Heart Transplantation; Heart, Artificial; Heart-Lung Bypass; hemodynamics; Hemorrhage; In Vitro; in vivo; Inferior vena cava structure; innovate; innovation; innovative; Laboratories; Left; Lung; Marketing; mechanical heart; Mechanics; Medication; Methods and Techniques; Methods, Other; minimally invasive; Myocardial Infarct; Myocardial Infarction; novel; Operation; Operative Procedures; Operative Surgical Procedures; Patients; Pharmaceutic Preparations; Pharmaceutical Preparations; Pigs; porcine; pre-clinical; preclinical; Preparation; programs; Programs (PT); Programs [Publication Type]; public health relevance; pulmonary; Pulmonary Artery; Pulmonary artery structure; Pulmonary Embolism; Pulmonary Hypertension; Pulmonary Valve; Pulmonary valve structure; Pulmonic Valve; Recovery; Research; research study; Respiratory System, Lung; Reticuloendothelial System, Blood; Right ventricular structure; Risk; Safety; SCHED; Schedule; Speed; Speed (motion); standard of care; success; suid; Suidae; Surface; surgery; Surgical; Surgical Interventions; Surgical Procedure; Swine; System; System, LOINC Axis 4; Techniques; Testing; transplant; Transplantation; Transplantation, Cardiac; Vascular constriction (function); Vasoconstriction; Vena Cava, Inferior; Ventricles, Right; Ventricular; ventricular assist device; verification and validation; Work Load; Workload

Phase II

Phase II year
2010 (last award dollars: 2010)
Phase II Amount
$499,962
This application addresses broad Challenge Area (04) Clinical Research and Specific Challenge Topic 04-HL-110 Treatment of pulmonary hypertension and right heart failure. The overall objective of this proposed program is the U.S. clinical introduction of the Impella RP system, a percutaneously introduced ventricular assist device (VAD) for treatment of acute right heart failure. The device will be a less traumatic alternative to surgically placed extracorporeal right ventricular assist devices (RVADs), the current standard of care for these patients. The Impella RP system is designed to reduce the workload of the right ventricle and promote cardiac recovery, providing flows of up to 4 lpm and up to 2 weeks of support. The program will comprise pre-clinical design verification and validation testing, regulatory filings to the FDA, and an Investigational Device Exemption (IDE) clinical trial to evaluate safety and effective hemodynamic support. Based upon the success of our proposed program, the next steps would be an application for FDA approval to market the device in the U.S. and preparation for clinical introduction.

Public Health Relevance:
Acute right heart failure is a significant clinical problem which often occurs in patients affected by pulmonary embolism, pulmonary hypertension, or heart attack, as well as in patients who have been treated with cardiopulmonary bypass, heart transplantation, or left heart mechanical circulatory support. Right ventricular failure that does not respond to medication is treated with mechanical circulatory support in the form of a right ventricular assist device (RVAD). Current surgically placed RVADs offer potential for rapid recovery, but are highly invasive and are associated with a host of complications including blood clots and bleeding. Therefore, a strong unmet clinical need exists for a minimally invasive and percutaneously placed RVAD that requires only a minimal level of anticoagulation. We estimate that up to 25,000 patients each year could benefit from such a short term RVAD.

Public Health Relevance Statement:
PROJECT NARRATIVE Acute right heart failure is a significant clinical problem which often occurs in patients affected by pulmonary embolism, pulmonary hypertension, or heart attack, as well as in patients who have been treated with cardiopulmonary bypass, heart transplantation, or left heart mechanical circulatory support. Right ventricular failure that does not respond to medication is treated with mechanical circulatory support in the form of a right ventricular assist device (RVAD). Current surgically placed RVADs offer potential for rapid recovery, but are highly invasive and are associated with a host of complications including blood clots and bleeding. Therefore, a strong unmet clinical need exists for a minimally invasive and percutaneously placed RVAD that requires only a minimal level of anticoagulation. We estimate that up to 25,000 patients each year could benefit from such a short term RVAD.

Project Terms:
Effectiveness ; Pharmaceutical Preparations ; drug/agent ; Pharmaceutic Preparations ; Medication ; Drugs ; Address ; ventricular assist device ; in vivo ; Preparation ; Characteristics ; Ventricular ; Cardiac ; Development ; developmental ; Acute myocardial infarction ; Acute myocardial infarct ; Femoral vein ; pre-clinical ; preclinical ; Affect ; base ; blood pump ; Heart failure ; cardiac failure ; Heart Transplantation ; heart transplant ; cardiac graft ; Heart Grafting ; Cardiac Transplantation ; Artificial Heart ; mechanical heart ; heart prosthesis ; cardiac prosthesis ; hemodynamics ; Hemorrhage ; blood loss ; Bleeding ; Left ; Area ; Surface ; Acute ; Clinical ; Pulmonary Hypertension ; In Vitro ; Right ventricular structure ; Right Ventricles ; Laboratories ; Failure (biologic function) ; failure ; FLR ; Recovery ; Lung ; pulmonary ; Lung Respiratory System ; Funding ; Marketing ; Myocardial Infarction ; heart infarction ; heart infarct ; heart attack ; coronary infarction ; coronary infarct ; coronary attack ; cardiac infarct ; Myocardial Infarct ; Cardiac infarction ; Blood Clot ; Patients ; Anticoagulation ; Pulmonary artery structure ; Pulmonary Artery ; Pulmonary Embolism ; Pulmonary valve structure ; Pulmonic Valve ; Pulmonary Valve ; Research ; Risk ; Safety ; programs ; Mechanics ; mechanical ; Family suidae ; suid ; porcine ; Swine ; Suidae ; Pigs ; Testing ; Transplantation ; transplant ; Vascular constriction (function) ; Vasoconstriction ; Inferior vena cava structure ; Inferior Vena Cava ; Techniques ; System ; LOINC Axis 4 System ; Operative Surgical Procedures ; surgery ; Surgical Procedure ; Surgical Interventions ; Surgical ; Operative Procedures ; Blood ; Blood Reticuloendothelial System ; Blood coagulation ; Blood Clotting ; success ; Speed (motion) ; Speed ; novel ; research study ; experimental study ; experimental research ; experiment ; Devices ; Cardiopulmonary Bypass ; heart bypass ; Heart-Lung Bypass ; Catheterization ; Cathetergram ; Workload ; Work Load ; Catheters ; Device Designs ; Schedule ; Clinical Research ; Clinical Study ; Clinical Trials ; clinical investigation ; cost ; design ; designing ; innovation ; innovative ; innovate ; public health relevance ; minimally invasive ; standard of care ; verification and validation ;